Valuation: Glenmark Pharmaceuticals Limited

Market Cap 731B 7.78B 6.99B 6.38B 5.83B 11B 11.34B 76.98B 30.83B 390B 29.21B 28.59B 1,234B P/E 2027 *
31.6x
P/E 2028 * 26.1x
Enterprise Value 695B 7.4B 6.64B 6.07B 5.55B 10.46B 10.79B 73.22B 29.32B 371B 27.78B 27.19B 1,173B EV / Sales 2027 *
4.1x
EV / Sales 2028 * 3.65x
Free-Float
51.04%
Yield 2027 *
0.15%
Yield 2028 * 0.16%
1 day+4.36%
1 week+12.67%
Current month+12.67%
1 month+12.07%
3 months+14.10%
6 months+8.93%
Current year+27.26%
1 week 2,306
Extreme 2306
2,682.5
1 month 2,101.6
Extreme 2101.6
2,682.5
Current year 1,842
Extreme 1842
2,682.5
1 year 1,807
Extreme 1807
2,682.5
3 years 722.1
Extreme 722.1
2,682.5
5 years 348.5
Extreme 348.5
2,682.5
10 years 161.65
Extreme 161.65
2,682.5
Manager TitleAgeSince
Chief Executive Officer 57 1999-12-31
Director of Finance/CFO 54 2025-05-26
President - 2023-09-14
Director TitleAgeSince
Director/Board Member 58 -
Chairman 57 2011-05-11
Director/Board Member 86 2009-08-13
Change 5-day change 1-year change 3-year change Capi.($)
+4.36%+12.67%+43.06%+242.84% 7.78B
-0.79%-4.48%+44.44%+127.49% 1,206B
+1.43%+1.11%+47.73%+82.08% 665B
+1.07%-1.21%+32.99%+106.31% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 207B
Average +0.36%-0.12%+40.67%+93.19% 418.75B
Weighted average by Cap. -0.04%-1.93%+42.24%+88.67%

Financials

2027 *2028 *
Net sales 169B 1.8B 1.62B 1.48B 1.35B 2.55B 2.63B 17.85B 7.15B 90.48B 6.77B 6.63B 286B 187B 1.99B 1.79B 1.64B 1.49B 2.82B 2.91B 19.73B 7.9B 100B 7.49B 7.33B 316B
Net income 23.69B 252M 226M 207M 189M 357M 368M 2.5B 999M 12.65B 947M 927M 39.99B 28.32B 302M 271M 247M 226M 426M 439M 2.98B 1.19B 15.12B 1.13B 1.11B 47.8B
Net Debt -35.75B -381M -342M -312M -285M -538M -555M -3.77B -1.51B -19.09B -1.43B -1.4B -60.34B -47.16B -502M -451M -412M -376M -710M -732M -4.97B -1.99B -25.18B -1.88B -1.84B -79.61B
Projected Income Statement - Annual - Glenmark Pharmaceuticals Limited
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
26-11-06 ₹2,590.00 +4.36% 5,036,760
26-11-05 ₹2,481.80 -0.91% 901,870
26-11-04 ₹2,504.70 +4.02% 717,669
26-11-03 ₹2,408.00 +1.09% 930,049
26-11-02 ₹2,382.00 +3.62% 1,549,673
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Glenmark Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,590.00INR
Average target price
2,512.82INR
Spread / Average Target
-2.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glenmark Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLENMARK Stock